TheraCryf (FRA:8EV) Days Payable : 0.00 (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is TheraCryf Days Payable?

TheraCryf's average Accounts Payable for the six months ended in Sep. 2023 was €0.47 Mil. TheraCryf's Cost of Goods Sold for the six months ended in Sep. 2023 was €0.00 Mil.

The historical rank and industry rank for TheraCryf's Days Payable or its related term are showing as below:

FRA:8EV's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.12
* Ranked among companies with meaningful Days Payable only.

TheraCryf's Days Payable stayed the same from Sep. 2022 (0.00) to Sep. 2023 (0.00).

TheraCryf Days Payable Historical Data

The historical data trend for TheraCryf's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Days Payable Chart

TheraCryf Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Days Payable

Get a 7-Day Free Trial

TheraCryf Semi-Annual Data
	Mar13	Mar14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of TheraCryf's Days Payable

For the Biotechnology subindustry, TheraCryf's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TheraCryf's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TheraCryf's Days Payable distribution charts can be found below:

* The bar in red indicates where TheraCryf's Days Payable falls into.

TheraCryf Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

TheraCryf's Days Payable for the fiscal year that ended in Mar. 2023 is calculated as

	Days Payable (A: Mar. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Mar. 2022 )	+	Accounts Payable (A: Mar. 2023 ))	/	count )	/	Cost of Goods Sold (A: Mar. 2023 )	*	Days in Period
=	( (0.079	+	0.456)	/	2 )	/	0	*	365
=	0.2675					/	0	*	365
=	N/A

TheraCryf's Days Payable for the quarter that ended in Sep. 2023 is calculated as:

	Days Payable (Q: Sep. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Mar. 2023 )	+	Accounts Payable (Q: Sep. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2023 )	*	Days in Period
=	( (0.456	+	0.481)	/	2 )	/	0	*	365 / 2
=	0.4685					/	0	*	365 / 2
=	N/A

TheraCryf Days Payable Related Terms

Thank you for viewing the detailed overview of TheraCryf's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

TheraCryf (FRA:8EV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (FRA:8EV) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

EVG:UK

Address

Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG

Website

https://www.evgen.com

Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.

TheraCryf (FRA:8EV) Headlines

No Headlines